- Home
- AVD vs HURA Comparison
AVD vs HURA Comparison
Compare AVD & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVD | HURA |
|---|---|---|
| Founded | 1969 | 2009 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Agricultural Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.4M | 112.4M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVD | HURA |
|---|---|---|
| Price | $2.06 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $10.00 |
| AVG Volume (30 Days) | 423.5K | ★ 721.8K |
| Earning Date | 03-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $515,114,000.00 | N/A |
| Revenue This Year | $8.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.11 | $0.41 |
| 52 Week High | $5.92 | $4.41 |
Technical Indicators
Market Signals| Indicator | AVD | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 13.94 | 55.05 |
| Support Level | N/A | $1.66 |
| Resistance Level | $5.34 | $1.83 |
| Average True Range (ATR) | 0.30 | 0.20 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 0.41 | 24.12 |
Price Performance
Historical ComparisonAbout AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.